Want to see JP:4574 full AI Analyst Report?
4574 Stock Chart & Stats
¥305.00
-¥2.00(-0.62%)
At close: 4:00 PM EST
¥305.00
-¥2.00(-0.62%)
Day’s Range― - ―
52-Week Range¥246.00 - ¥335.00
Previous CloseN/A
Volume146.60K
Average Volume (3M)93.84K
Market Cap
¥13.92B
Enterprise Value¥11.47K
Total Cash (Recent Filing)¥4.14B
Total Debt (Recent Filing)¥1.32B
Price to Earnings (P/E)26.1
Beta0.65
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.19%
Share Statistics
EPS (TTM)8.23
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.9
Revenue Forecast (FY)¥6.75B
Bulls Say, Bears Say
Bulls Say
Improved Leverage And Balance-sheet FlexibilityMaterial debt reduction meaningfully lowers refinancing and liquidity risk, giving management durable financial flexibility to fund R&D, manufacturing or partnerships without heavy reliance on external capital. A stronger balance sheet supports long-term strategic optionality and resilience through cycles.
Return To Positive Operating And Free Cash FlowSustained positive operating and free cash flow provides an ongoing internal funding source for operations and reinvestment, reducing dependence on new debt or equity. If maintained, this supports durable capital allocation toward growth, dividends, or debt reduction.
Stabilizing And Modestly Growing RevenuesConsistent modest revenue growth after a multi-year trough indicates improving commercial traction and demand stability. Over 2–6 months this supports better predictability of margins and cash generation, enabling more reliable planning for production and R&D investments.
Bears Say
Multi-year Earnings And Cash-flow VolatilityHistoric swings in profitability and cash flow reduce visibility into recurring earnings power and complicate long-term planning. Persistent volatility can impair sustained investment in pipelines and dampen stakeholder confidence, making durable forecasting and strategy execution harder.
Cash Conversion And Earnings Quality Not Fully ProvenIf reported profits do not consistently convert into operating cash, the business may face working-capital strains or episodic financing needs. Weak cash conversion undermines the durability of earnings and limits reliable funding for launches, capex, or shareholder returns.
Shrinking Asset Base And Prior Deep Negative ROEA declining asset base and historical negative ROE signal past operational deterioration and potential erosion of scale or productive capacity. Restoring asset-backed growth and consistent returns may require sustained investment and time, constraining near-term competitive expansion.
Taiko Pharmaceutical Co., Ltd. News
4574 FAQ
What was Taiko Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Taiko Pharmaceutical Co., Ltd. lowest stock price was ¥246.00 and its highest was ¥335.00 in the past 12 months.
What is Taiko Pharmaceutical Co., Ltd.’s market cap?
Taiko Pharmaceutical Co., Ltd.’s market cap is ¥13.92B.
When is Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Taiko Pharmaceutical Co., Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 23 days.
How were Taiko Pharmaceutical Co., Ltd.’s earnings last quarter?
Taiko Pharmaceutical Co., Ltd. released its earnings results on May 14, 2026. The company reported -¥1.89 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Taiko Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Taiko Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Taiko Pharmaceutical Co., Ltd. pay dividends?
Taiko Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥3.5 which represents an annual dividend yield of 1.19%. See more information on Taiko Pharmaceutical Co., Ltd. dividends here
What is Taiko Pharmaceutical Co., Ltd.’s EPS estimate?
Taiko Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Taiko Pharmaceutical Co., Ltd. have?
Taiko Pharmaceutical Co., Ltd. has 50,636,900 shares outstanding.
What happened to Taiko Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Taiko Pharmaceutical Co., Ltd. reported an EPS of -¥1.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Taiko Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4574
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Taiko Pharmaceutical Co., Ltd.
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A brands, which are formulated to alleviate symptoms such as loose stools, diarrhea, vomiting, and ailments stemming from food or water contamination. Additionally, it provides specific tablets for diarrhea relief and quasi-pharmaceuticals like the Trumpet Intestinal Regulator BF. In its infection control segment, Taiko Pharmaceutical produces and supplies a range of sanitation products under the Cleverin brand to wholesalers. This includes the Cleverin generator, a device engineered to emit low concentrations of chlorine dioxide gas. The company also leverages its proprietary Cleverin technology by supplying it through original equipment manufacturer (OEM) agreements and engaging in joint product development ventures with other businesses. Its products are exported to several countries, including the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
Nippon Chemiphar Co., Ltd.
―